Lynchburg Journal of Medical Science
The Role of Extended Prophylactic Anticoagulant Treatment in Reducing the Risk of Recurrent Venous Thromboembolism
Dr Elyse Watkins
There is an increased risk of thrombosis recurrence after completing the initial three to six-month treatment for acute unprovoked venous thromboembolism (VTE). Numerous studies have discovered that extended prophylactic anticoagulant therapy can lower recurrence rates, which in turn can help reduce mortality. Therefore, due to the significant risk of recurrent VTE, clinicians must consider extended anticoagulant treatment for high-risk patients. This clinical review summarises the most recent evidence on the long-term preventative use of direct oral anticoagulants (DOACs), warfarin, and aspirin in the treatment of VTE. Further research is warranted to determine the actual risk of bleeding with indefinite anticoagulation treatment. In addition, research is necessary to identify patients at high risk of VTE recurrence and the optimal duration of treatment for secondary prevention.
Bhakar T. The Role of Extended Prophylactic Anticoagulant Treatment in Reducing the Risk of Recurrent Venous Thromboembolism. Lynchburg Journal of Medical Science. 2023; 5(1).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.